The litigation, spearheaded by The Gross Law Firm, centers on allegations that ARS Pharmaceuticals misled shareholders regarding the timeline for securing expanded insurance coverage through CVS Caremark. While company leadership previously painted a positive picture of the rollout, a June 24 disclosure revealed that coverage would not be finalized until January 2027—missing the vital summer and back-to-school allergy seasons.

This revelation prompted an immediate market correction, with the company's stock price tumbling from $10.54 to $8.02 in a single session. Shareholders who suffered losses during this period are eligible to participate in the recovery effort. Registration for the action does not require immediate appointment as a lead plaintiff, and participants gain access to portfolio monitoring services to track the case as it moves through the courts.